AORTIC VALVE REPLACEMENT WITH SUTURELESS PERCEVAL BIOPROSTHESIS IN RIGHT ANTERIOR MiNITHORACOTOMY APPROACH: SINGLE CENTER EXPERIENCE WITH 400 IMPLANTS
Minimally invasive approach (MIA) reduces mortality and morbidity in patients referred for aortic valve replacement (AVR). Sutureless technology facilitates MIA. We describe our experience with sutureless Perceval (LivaNova, Italy) aortic bioprosthesis in right anterior minithoracotomy approach.
Between March 2011 and February 2016, 631 patients underwent AVR with Perceval bioprosthesis. Right anterior minithoracotomy approach was performed in 400 patients (63%). Mean age was 77 ± 6 years, 255 patients were female (64%), and mean logistic EuroSCORE was 10.1 ± 7.3%.
In-hospital mortality was 0.7% (3/400). Cardiopulmonary bypass and aortic cross-clamp times were 82.3 ± 30.8 and 52 ± 21.6 minutes. At mean follow-up of 16.6 ± 12.4 months, survival was 97.2%, freedom from reoperation was 99.2%, and mean transvalvular pressure gradient was 11.7 ± 5.01 mmHg.
AVR with Perceval bioprosthesis in right anterior minithoracotomy approach is a safe and feasible procedure associated with low mortality and excellent hemodynamic performance. Sutureless technology facilitates minithoracotomy approach.